BioWorld

July 3, 2002

ARYx Raises $25M To Develop Drugs Using Retrometabolics

ARYx Therapeutics Inc. raised $25 million in a Series C round of financing - it's largest to date - and will use the funds to continue its progress as the Volvo of the drug industry. (BioWorld Today) Read More

Centocor's Remicade Approved For Another Crohn's Indication

Plumbing Molecular Depths Of Asthma's Symptoms Turns Up 2 Culprits: Interleukin-13, STAT6

Medisyn's 'Forward Engineering' Technology Used In Cancer Effort

Holiday Notice

Other News To Note

U.S. Patent Disclosures

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 4, 2025.

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B

BioWorld

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual glucagon-like peptide 1...

Pharma execs speak out: UK pricing rebates scare investors

BioWorld

The row between pharma companies and the U.K. government over rebates has intensified, with the Association of the British Pharmaceutical Industry calling up its...

ASCO 2025: Verastem has positive cancer data but stock sags

BioWorld

New dose-escalation data from Verastem Oncology’s phase I/II cancer study in China prompted the company to say it was encouraged by the efficacy results. However,...